A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.
about
Driving chronicity in rheumatoid arthritis - perpetuating role of myeloid cells.What are the dominant cytokines in early rheumatoid arthritis?Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.Bone Loss in Rheumatoid Arthritis: Basic Mechanisms and Clinical Implications.Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab.Model-Based Discovery and Development of Biopharmaceuticals: A Case Study of Mavrilimumab.Increased Frequency of Peripheral B and T Cells Expressing Granulocyte Monocyte Colony-Stimulating Factor in Rheumatoid Arthritis Patients.Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism.Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.TNF and granulocyte macrophage-colony stimulating factor interdependence mediates inflammation via CCL17.Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies.Novel Therapeutic Targets in Axial Spondyloarthritis.GM-CSF Quantity Has a Selective Effect on Granulocytic vs. Monocytic Myeloid Development and Function
P2860
Q47189951-6DFFF9FF-D26C-47F7-A3C5-DE7729DB3AA4Q47366363-BEEA3574-8CC0-4175-933B-05769FB8EB7FQ47604956-EB3B3A39-079A-48E4-93FF-795C2A6E95E4Q47755963-E6832B0D-F9E4-4997-BC0D-F86F5EC87776Q47800990-CE97939A-FC61-4E5C-A8EC-B3BBD4131458Q49393096-BB661A35-0DB9-43E9-8721-F71036423AD3Q49447486-9332DAEF-5179-4666-BB95-631F5456142AQ49630708-35C9D917-7488-4019-A91B-F1FAA9F840A9Q50047899-DDF17139-8794-4EED-A2C6-5B1739B92C32Q50110839-84790411-79C5-4FF5-A391-D0E4C39EA581Q52644010-0B699C37-D24A-4792-950F-91C5512F6EC9Q55025616-44669921-3F99-4BD6-BC6B-3190091059A7Q55311646-DED10CF3-14F7-4DEC-955C-0950DB54A96DQ58698466-7A4E64BA-29B5-4745-A41E-0AE133BBAF5F
P2860
A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
A randomised phase IIb study o ...... tment of rheumatoid arthritis.
@en
type
label
A randomised phase IIb study o ...... tment of rheumatoid arthritis.
@en
prefLabel
A randomised phase IIb study o ...... tment of rheumatoid arthritis.
@en
P2093
P50
P1476
A randomised phase IIb study o ...... tment of rheumatoid arthritis.
@en
P2093
Alex Godwood
Andrea Rubbert-Roth
Chi-Yuan Wu
David Close
Dominic Sinibaldi
EARTH EXPLORER 1 study investigators
Eduardo Mysler
Iain B McInnes
Joel Kremer
P304
P356
10.1136/ANNRHEUMDIS-2016-210624
P407
P577
2017-02-17T00:00:00Z